possible side-effects. These blood tests include haematology, renal and liver function parameters, and measurement of tumour markers. For response evaluation after therapy, imaging is done in addition to these blood tests. In 2013 van Vliet and coworkers
Search Results
Tessa Brabander, Wouter A van der Zwan, Jaap J M Teunissen, Boen L R Kam, Wouter W de Herder, Richard A Feelders, Eric P Krenning, and Dik J Kwekkeboom
Louis de Mestier, Clarisse Dromain, Gaspard d'Assignies, Jean-Yves Scoazec, Nathalie Lassau, Rachida Lebtahi, Hedia Brixi, Emmanuel Mitry, Rosine Guimbaud, Frédéric Courbon, Michèle d'Herbomez, and Guillaume Cadiot
evaluating NET responses must also take these differences into account. Currently, the evaluation of NET therapeutic responses is mainly based on Radiological Response Evaluation Criteria In Solid Tumors v1.1 (RECIST; Eisenhauer et al . 2009 ). However, as
Kimberly Kamp, Brenda Gumz, Richard A Feelders, Dik J Kwekkeboom, Gregory Kaltsas, Frederico P Costa, and Wouter W de Herder
moderately differentiated tumors ( Rindi et al . 2006 , 2007 ). At baseline, all patients had radiological documentation of PD according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.0 ( Therasse et al . 2000 ). All patients had given
Chen Wang, Xin Zhang, Xue Yang, Hui Li, Ruixue Cui, Wenmin Guan, Xin Li, Zhaohui Zhu, and Yansong Lin
proven effective against RAIR-DTC ( Schlumberger et al . 2015 , Lin et al . 2017 ). Traditionally, patients with RAIR-DTC were evaluated every 2 months after the therapy using the Response Evaluation Criteria in Solid Tumors (RECIST) based on
James C Yao, Jonathan Strosberg, Nicola Fazio, Marianne E Pavel, Emily Bergsland, Philippe Ruszniewski, Daniel M Halperin, Daneng Li, Salvatore Tafuto, Nitya Raj, Davide Campana, Susumu Hijioka, Markus Raderer, Rosine Guimbaud, Pablo Gajate, Sara Pusceddu, Albert Reising, Evgeny Degtyarev, Mark Shilkrut, Simantini Eddy, and Simron Singh
start. Additional inclusion criteria included an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2, presence of ≥1 measurable lesion according to response evaluation criteria in solid tumors (RECIST) 1.1 per Investigator’s assessment
Clemens Kratochwil, Ruben López-Benítez, Walter Mier, Sabine Haufe, Berend Isermann, Hans-Ulrich Kauczor, Peter L Choyke, Uwe Haberkorn, and Frederik L Giesel
metastases according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.0 criteria of 15 patients (patient numbering corresponding to Table 1 ). Overall response (complete and partial remission) was observed in nine of the 15 patients (60%). In 14 of
J Cros, O Hentic, V Rebours, M Zappa, N Gille, N Theou-Anton, D Vernerey, F Maire, P Lévy, P Bedossa, V Paradis, P Hammel, P Ruszniewski, and A Couvelard
proposed regardless of previous therapeutic line in case of progression of metastases according to Response Evaluation Criteria in Solid Tumors (RECIST) guidelines on two consecutive imaging procedures performed at 6-month intervals and/or when liver burden
J R Strosberg, J A Chan, D P Ryan, J A Meyerhardt, C S Fuchs, T Abrams, E Regan, R Brady, J Weber, T Campos, L K Kvols, and M H Kulke
metastatic well-differentiated (low or intermediate grade) carcinoid or pNETs. Patients without clinical evidence of a pancreatic primary site were considered to have carcinoid tumors. Patients were required to have evidence of progressive disease by Response
M Cives, P L Kunz, B Morse, D Coppola, M J Schell, T Campos, P T Nguyen, P Nandoskar, V Khandelwal, and J R Strosberg
). Patients with a tumoral ki-67 index of over 20% were excluded. Previous systemic antineoplastic treatment, including octreotide and lanreotide, was not permitted. Other key eligibility criteria were measurable disease by Response Evaluation Criteria in
Kimberly Perez, Heather Jacene, Jason L Hornick, Chao Ma, Nuno Vaz, Lauren K Brais, Holly Alexander, William Baddoo, Kristina Astone, Edward D Esplin, John Garcia, Daniel M Halperin, Matthew H Kulke, and Jennifer A Chan
Radiologic response was assessed retrospectively by an independent radiologic review of available scans. Tumor response was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. All lesions up to a maximum of ten representative